Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.
Company codeALUR_t
Company nameAllurion Technologies Inc
IPO dateMar 29, 2021
Founded at2023
CEODr. Shantanu Gaur, M.D.
Number of employees- -
Security type- -
Fiscal year-end- -
Address11 Huron Dr Ste 200
CityNATICK
Stock exchange- -
CountryUnited States of America
Postal code01760
Phone15086474000
Websitehttps://www.allurion.com/en
Company codeALUR_t
IPO dateMar 29, 2021
Founded at2023
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data